News articles about Cidara Therapeutics (NASDAQ:CDTX) have trended positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cidara Therapeutics earned a daily sentiment score of 0.30 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.9603879636003 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of brokerages recently weighed in on CDTX. Cantor Fitzgerald set a $15.00 price target on shares of Cidara Therapeutics and gave the company a “buy” rating in a report on Friday, January 19th. HC Wainwright lifted their target price on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, Zacks Investment Research lowered shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, December 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Cidara Therapeutics presently has a consensus rating of “Buy” and an average price target of $13.56.
Cidara Therapeutics (NASDAQ CDTX) traded up $0.20 on Tuesday, reaching $6.75. 63,000 shares of the company’s stock were exchanged, compared to its average volume of 76,234. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.16. Cidara Therapeutics has a 12-month low of $5.60 and a 12-month high of $8.80. The firm has a market cap of $136.61 and a price-to-earnings ratio of -1.99.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.